First AD

Second AD

Dr.'s Cluzeau and Komajdi on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data 

Dr. Thomas Cluzeau: Utilization patterns of luspatercept in LR-MDS

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 

Peer Exchange

Medical professionals examine the utilization patterns of luspatercept in lower-risk myelodysplastic syndromes (LR-MDS) and their impact on patient treatment strategies. 

Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data 

Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification 

Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS  

Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies 

Review of the COMMANDS Trial

Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial 

Clinical Implications of COMMANDS Trial in Clinical Practice  

Treatment Decision-Making Based on the COMMANDS Trials 

Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024 

Safety Profile of Available Frontline Treatments LR-MDS 

1L treatment of lower-risk MDS beyond luspatercept 

Sequencing Second-Line Treatments for LR-MDS

Perspectives of IMerge Study

Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024 

EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates   

Final Thoughts on EHA 2024 Data for Lower-Risk MDS